BastianHMRosemanJMMcGwinGJrSystemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosisLupus.2002113152–160 1:STN:280:DC%2BD383msFaltg%3D%3D10.1191/0961203302lu158oa
2.
CaprioliJNorisMBrioschiSGenetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcomeBlood.200610841267–1279 1:CAS:528:DC%2BD28Xot1ymtbk%3D10.1182/blood-2005-10-007252
3.
CaveroT, RabascoC, LopezA, et al. Eculizumab in secondary atypical haemolytic uraemic syndrome.Nephrol Dial Transplant.2017;32(3):466–474.
JozsiM, LichtC, StrobelS, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency.Blood. 2008;111(3):1512–1514.
6.
KaplanBS, MeyersKE, SchulmanSL. The pathogenesis and treatment of hemolytic uremic syndrome.J Am Soc Nephrol.1998;9(6):1126–1133.
7.
KelloN, KhouryLE, MarderG, FurieR, ZapantisE, HorowitzDL. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature.Semin Arthritis Rheum.2019;49(1):74–83.
8.
KhoslaJ, YehAC, SpitzerTR, DeyBR. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies.Bone Marrow Transplant.2018;53(2):129–137.
9.
LegendreCM, LichtC, MuusP, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.N Engl J Med.2013;368(23):2169–2181.
10.
LegendreCM, CampistolJM, FeldkampT, et al. Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis.Transpl Int.2017;30(12):1275–1283.
11.
LichtC, GreenbaumLA, MuusP, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.Kidney Int. 2015;87(5):1061–1073.
12.
Mejia-ViletJM, Cordova-SanchezBM, Uribe-UribeNO, Correa-RotterR, Morales-BuenrostroLE. Prognostic significance of renal vascular pathology in lupus nephritis.Lupus. 2017;26(10):1042–1050.
NorisM, CaprioliJ, BresinE, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.Clin J Am Soc Nephrol.2010;5(10):1844–1859.
RouxT, DebsR, MaisonobeT, et al. Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases.J Peripher Nerv Syst2018;23(4):235–240.
17.
SchwartzN, StockAD, PuttermanC. Neuropsychiatric lupus: new mechanistic insights and future treatment directions.Nat Rev Rheumatol.2019;15(3):137–152.
18.
ScullyM, CatalandS, CoppoP, de la RubiaJ, FriedmanKD, Kremer HovingaJ, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.J Thromb Haemost.2017;15(2):312–322.
19.
SongD, WuLH, WangFM, YangXW, ZhuD, ChenM, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis.Arthritis Res Ther.2013;15(1):R12.
20.
VinaER, FangAJ, WallaceDJ, WeismanMH. Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome.Semin Arthritis Rheum.2005;35(3):175–184.
21.
WangS, WuM, ChiribogaL, ZeckB, BelmontHM. Membrane attack complex (mac) deposition in lupus nephritis is associated with hypertension and poor clinical response to treatment.Semin Arthritis Rheum.2018;48(2):256–262.
